Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product

一种丝氨酸水解酶、受体激动剂的技术，应用在含有效成分的医用配制品、羟基化合物有效成分、有机活性成分等方向，能够解决分开、限制直接CB1激动剂医疗使用等问题

Pending Publication Date: 2021-10-29
MEDIPUR PHARM CORP
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, it has proven difficult to separate these beneficial and unfavorable properties, thus limiting the medical use of direct CB1 agonists

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
  • Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
  • Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product

Examples

Experimental program
Comparison scheme
Effect test

example 15

[0053] Cannabis plant material derived from hemp plants having a relatively high CBD (eg CBDA and / or CBD) content is preferably used. For example, through the use of standard selective breeding techniques, cannabis varieties with high CBD content can be developed, for example, varieties that can (for example) have a CBDA / CBD content >90% of the total cannabinoid content, e.g., Charlotte's Web or Arvid Avidekal.

[0054] If the plant material from which CBD is to be prepared contains significant amounts of the cannabinoid acid CBDA, the plant material can be subjected to a decarboxylation step to convert the CBDA to the free cannabinoid CBD. This can be done prior to the preparation of the CBD-containing plant extract or can form part of this extraction process.

[0055] A "substantially pure" preparation of a cannabinoid such as, for example, cannabidiol (CBD) is defined as having a chromatographic purity of 95% or greater, more preferably 96% or greater, more preferably 97% ...

Embodiment

[0115] These and other objects and features of the invention will become apparent from the following examples. As described, the following examples are not intended to be viewed as limitations on the scope of the invention.

[0116] The skilled artisan will readily appreciate that various changes can be made to the examples and indications provided herein. For example, the purification and formulation of CBD can be altered.

[0117] Extraction and Purification of Cannabidiol (CBD)

[0118] Cannabinoids (CBD) are extracted and purified to greater than 95% purity from high CBD cannabis strains by using a combination of supercritical fluid extraction and chromatography techniques known in the scientific arts. CBD can also be synthesized using chemical synthesis techniques known in the scientific arts.

[0119] Dried cannabis buds are harvested from a cannabinoid-enriched (12.5% ​​w / w by dry weight) strain. The dried buds are extracted with a solvent, thereby obtaining an extr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are formulations for treating affective mood disorders. The formulations comprise one or more than one CB receptor agonist and one or more than one serine hydrolase enzyme inhibitor.

Description

technical field [0001] The present disclosure relates to formulations for the treatment of mood disorders. In particular, the present disclosure relates to formulations that combine one or more cannabinoid receptor agonists and one or more serine hydrolase inhibitors for the treatment of mood disorders. Background technique [0002] Anxiety stems from and contributes to dysregulation of neurobiological systems, but the precise mechanisms of anxiety disorders are still only partially understood. Low levels of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces central nervous system activity, can contribute to anxiety. Some anxiolytics achieve their effects by modulating GABA receptors. [0003] GABA receptors are a class of receptors that respond to GABA, the major inhibitory transmitter in the mature vertebrate central nervous system. There are two types of GABA receptors: GABA A (or GABA(A)) and GABA B (or GABA(B)). GABA A The receptors are ligand-gated ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4525A61K31/05A61P25/22C07C39/23C07D405/06
CPCA61K31/05A61K31/4525A61P25/22A61K45/06A61K2300/00
Inventor R·提瓦里-潘迪R·D·科德卡拉N·R·潘迪
Owner MEDIPUR PHARM CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com